Fig. 2.

Hepatic gene expression and plasma lipid parameters in male human apoA-I-transgenic mice treated daily for 5 days with either vehicle, RO5186026 (30 mg/kg), FXR-450 (30 mg/kg), the X-Ceptor compound (30 mg/kg), GW4064 (100 mg/kg), or TCA (2,000 mg/kg). A: Human and murine apoA-I and SHP expression was measured by quantitative PCR and normalized to GAPDH (N = 6/grp). Plasma total cholesterol, HDL-C, and human apoA-I levels were measured as described in Materials and Methods (N = 6/grp). Significant differences between the experimental groups (* P < 0.05) were determined by ANOVA followed by a Dunnett's T-test. Values are means ± SD. B: Pooled plasma lipoprotein FPLC profiles of mice treated with either vehicle, RO5186026, the X-Ceptor compound, or TCA.